Serious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist

Similar documents
Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient

FRANZCO, MD, MBBS. Royal Darwin Hospital

Clinically Significant Macular Edema (CSME)

The Human Eye. Cornea Iris. Pupil. Lens. Retina

Diabetic Retinopatathy

A Patient s Guide to Diabetic Retinopathy

Chronic eye diseases. Title of section divider. What s new, and how GPs can help. Eg. Case Study 1. Dr Jesse Gale, ophthalmologist

Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?

PART 1: GENERAL RETINAL ANATOMY

Mild NPDR. Moderate NPDR. Severe NPDR

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington

Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic


Diabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012

THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION

Diabetes and Eye Health more than meets the eye Vision Initiative - in association with PSA

Diabetic Retinopathy

Facts About Diabetic Eye Disease

Diabetes & Your Eyes

Medical Retina 2011 Nicholas Lee

Diabetic Management beyond traditional risk factors and LDL-C control: Can we improve macro and microvascular risks?

Diabetic Retinopathy A Presentation for the Public

GENERAL INFORMATION DIABETIC EYE DISEASE

Common Causes of Vision Loss

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)

Diabetic Retinopathy

New Developments in the treatment of Diabetic Retinopathy

Understanding Diabetic Retinopathy

Brampton Hurontario Street Brampton, ON L6Y 0P6

FROM OUTDATED TO UPDATED Eminence-Based Medicine

International Journal of Health Sciences and Research ISSN:

Diabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel

Diabetic Eye Disease

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

Ophthalmology Macular Pathways

Measures have been taken, by the Utah Department of Health, Bureau of Health Promotions, to ensure no conflict of interest in this activity.

OCCLUSIVE VASCULAR DISORDERS OF THE RETINA

RETINAL CONDITIONS RETINAL CONDITIONS

Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May

Age-Related Macular Degeneration (AMD)

MANAGING DIABETIC RETINOPATHY. <Your Hospital Name> <Your Logo>

Clinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital

Clinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.

ILUVIEN IN DIABETIC MACULAR ODEMA

Age-Related Eye Diseases and Conditions. Jonathan M. Frantz, MD, F.A.C.S. Cataract and Refractive Surgeon

Recalcitrant Diabetic Macular Oedema: Therapeutic Options

Treatment of Retinal Vein Occlusion (RVO)

Introduction How the eye works

RVO RETINAL VEIN OCCLUSION

Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema

Prevalence and causes of macular edema and its correlation: an observational study

Vascular Disease Ocular Manifestations of Systemic Hypertension

Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina

Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012

Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec

Outline. Preventing & Treating Diabetes Related Blindness. Eye Care Center Doctors. Justin Kanoff, MD. Eye Care Center of Northern Colorado

FA Conference. Lara Rosenwasser Newman, M.D. 10/2/14 University of Louisville Department of Ophthalmology and Visual Sciences

Diabesity A Public Health Crisis: AOA Evidence Based Translation to Care Series

Information for patients

DIABETIC RETINOPATHY (DR) PREFERRED PRACTICE PATTERNS (PPP) Philippines 2016

Retinal Diseases. Age-Related Macular Degeneration. What Is AMD? Risk Factors for AMD

Diabetic and the Eye: An Introduction

Diabetic Retinopathy Screening in Hong Kong. Dr. Rita Gangwani M.S, FRCS (Ophth), FCOphth(HK), FHKAM Eye Institute, The University of Hong Kong

Diabetic Macular Oedema To treat or not to treat?

DIABETIC RETINOPATHY

Past ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control

Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema

Diabetic Retinopathy

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.

Diabetic retinopathy damage to the blood vessels in the retina. Cataract clouding of the eye s lens. Cataracts develop at an earlier age in people

PROGRESSION OF DIABETIC RETINOPATHY FOLLOWING CATARACT SURGERY

Paradigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor

Study of 189 Cases of Diabetic Retinopathy at CMC Larkana

ZEISS AngioPlex OCT Angiography. Clinical Case Reports

Intravitreal Injection

Venous Occlusive Diseases

Preparing for laser treatment for diabetic retinopathy and maculopathy

Information for Patients undergoing Intravitreal Triamcinolone Acetonide (Kenalog) Injection

What is Age-Related Macular Degeneration?

OCT Assessment of the Vitreoretinal Relationship in CSME

There are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.

Optical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP

GRADUAL LOSS OF VISION. Teresa Anthony Consultant Ophthalmologist Emersons Green NHS Treatment Centre Bristol

NEPTUNE RED BANK BRICK

DIABETIC RETINOPATHY

Slide notes: The major chronic complications of diabetes mellitus are described here. Among these, microvascular complications have an important

Glaucoma Clinical Update. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012

RANZCO Screening and Referral Pathway for Diabetic Retinopathy #

Fundus Fluorescein Angiography in Diabetic Retinopathy: Correlation of Angiographic Findings to the Clinical Maculopathy Abstract: Purpose:

*Pleasesee amendment forpennsylvaniamedicaid at the endofthis CPB.

Front Line Diabetic Retinopathy What Not to Miss and Why

A retrospective nonrandomized study was conducted at 3

Diabetic Retinopathy What You Should Know. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute

Ophthalmology. Juliette Stenz, MD

ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS

EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD

10/8/13. the diabetes epidemic: strategies for saving sight. financial disclo$ure. unlabeled-investigative use disclosure

MAGNITUDE OF DIABETIC EYE DISEASE IN INDIA

Transcription:

Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist

5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions Diabetic retinopathy

20 18 16 14 12 10 8 6 4 2 0 Causes of global blindness in millions of people (WHO 2002 excludes uncorrected refractive errors ) A. Foster S.Resnikoff. The impact of vision 2020 on global blindness. Eye 2005; 19:1133-1135

Cataract

Cataract Cataract is an opacity of the lens of the eye Symptoms may depend upon the type and morphology of the cataract Steroid drops or tablets may worsen the cataract if taken for a long period. No drops will reverse the cataract. Homeopathy! Treatment is by surgery

Cataract..blurred vision

Treatment Does it bother the patient enough that they want surgery Does the patient drive? Threshold for DVLA criteria 6/10 Does the patient have any other conditions 33% will have macular degeneration 15% will have glaucoma 5% will have diabetic retinopathy Most patients will have a guarded prognosis depending upon their other eye conditions Only 30-35% will have no other ocular disease

Phacoemulsification Small incision surgery Generally 2.65 to 2.75 mm surgery New Phacoemulsification machine Reduced surgery to 2.2 mm Stable anterior chamber More controlled & efficient cataract surgery You can see the surgery at

NHS restrictions Sutton and Merton CCG ; VA below 6/9.5 or less on Snellen chart ( DVLA criteria for driving is 6/10) Surrey CCG ; 1 st eye 6/9, 2 nd eye 6/18 or less

Outcomes 95-98% will have no complications All patients will need spectacles for near as well as distance Relative spectacle independence Steroid drops for 4-6 weeks Upto 25% will have capsular opacification 2-3 years after surgery. This can be treated with Nd YAG laser. New cataract machine at Ashtead ( old one replacement) Nd-YAG laser is already at Ashtead

Glaucoma

Glaucoma is a group of diseases Glaucoma is primarily a disease of the optic nerve with progressive loss of neurons & characteristic changes at the optic nerve Modifiable risk factors IOP Smoking Hypertension Cannot be reversed but can be slowed down Most common form : Primary open angle glaucoma irreversible visual loss over years Most acute form: Acute angle closure glaucoma irreversible visual loss over 24-72 hours

What can the patient see & what is the problem

How to detect Check for family history.. Positive family history + should have yearly check At least, yearly optician or ophthalmologist review if IOP raised 3 glaucoma tests

Treatment Drops Category Generic name Company name Beta Blockers Timolol 0.5% Timolol 0.25% Prostaglandin Inhibitors Latanoprost Bimatoprost Lumigan Travoprost Travatan Combinations Timolol/ Latanoprost Timolol / Bimatoprost Ganfort Timolol / Travoprost Duotrav Carbonic anhydrase inhibitors Brinzolamide Azopt Dorzolamide Trusopt Acetazolamide (oral) alpha agonist Brimonidine Alphagan alpha 2adrenoreceptor agonist Apraclonidine Iopidine

Surgery 1-5% of glaucoma patients may need surgery if their disease, IOP control is not satisfactory Trabaeculectomy Viscocanalostony Non penetrating eye surgery

Macular degeneration

Rapidly progresssive wet AMD Slowly progressive Dry AMD

Dry macular degeneration 90% Untreatable Slowly progressive Stop smoking Multivitamins Leutin, Zinc, Omega 3 Magnifying glasses Low vision aids CVI

LVA An optical low-vision aid, such as magnifiers, illuminated magnifiers, hand-held magnifiers or flat magnifiers. Aids for viewing faraway objects include monoculars and binoculars. Non-optical low-vision aids include everything from an anglepoise lamp Bold-print books? Kindle paperwhite, Kobo, Ipads Talking clocks Liquid level indicators that beep to prevent you burning yourself when using hot water.

WHAT THEY SEE Typical symptoms of advanced AMD Self Monitoring : Amsler Grid is not a substitute for an ophthalmic review. It allows patients to check their eyesight regularly for possible symptoms of macular degeneration. http://www.blindness.org/content.asp?id=46

Wet AMD Rapidly progressive Severe visual loss Treatable with Intravitreal injections of Lucentis Intravitreal injections of Eyelea Intravitreal injections of Avastin Photodynamic therapy with Verteporfin Stereotactic radiotherapy 80 % chance of stabilization of vision over 2 years 20 % chance of deterioration After 2 years, chances of stabilization decrease to 50-60%

ETDRS Letters MARINA - Secondary Endpoint Mean change in visual acuity over time 10 8 6 4 *P<0.0001 vs. sham +7.2 +6.5 17.7 letter benefit 2 0-2 0 1 2 3 4 5 6 7 8 9 10 11 12-4 -6-8 -10-12 Sham (n=238) Ranibizumab 0.3mg Ranibizumab 0.5mg (n=238) (n=240) Visit (months) -10.5 17.0 letter benefit

Retinal Vein occlusions

RVO Sudden onset Vascular risk factors BP, undiagnosed /under treated diabetes, high cholesterol, blood dyscrasias, haematological abnormalities Central retinal vein occlusion more damage poorer prognosis Branch retinal vein occlusion less damage better prognosis OCT --- Macular odema FFA --- Ischaemia vascular blood flow Treatment Aspirin / Plavix / Clopidogrel / warfarin Aggressively treat BP, DM, Cholesterol. Look for blood disorders

Ocular treatment for RVO Laser treatment for BRVO and macular odema Ozurdex retinal implant for BRVO or CRVO + macular odema Ischaemic RVO with rubeosis PRP laser ( very poor prognosis anyway )

Diabetic retinopathy

Diabetic Retinopathy Epidemiology The best predictor of diabetic retinopathy is the duration of the disease After 20 years of diabetes, nearly 99% of patients with type 1 diabetes and 60% with type 2 have some degree on diabetic retinopathy 33% of patients with diabetes have signs of diabetic retinopathy People with diabetes are 25 times more likely to become blind than the general population. Ophthalmology Myron Yanoff MD and Jay S. Duker Basic and Clinical Science Course, Section 12: Retina and Vitreous AAO http://www.aao.org/eyecare/news/upload/eye-health-fact-sheet.pdf -

RISK FACTORS Duration of DM Control of DM. Will not prevent but delays Hypertension Renal Disease Pregnancy Obesity, hyperlipidaemia, smoking, anaemia http://one.aao.org/ce/practiceguidelines/ppp_content.aspx?cid=d0c853d3-219f-487b-a524-326ab3cecd9a

Diabetic retinopathy symptoms Diabetic retinopathy is asymptomatic in early stages of the disease As the disease progresses symptoms may include Blurred vision Floaters Fluctuating vision Distorted vision Dark areas in the vision Poor night vision Impaired color vision Partial or total loss of vision

The Effect of Intensive Diabetes Treatment On the Progression of Diabetic Retinopathy In Insulin- Dependent Diabetes Mellitus T Intensive control reduced the risk of developing retinopathy by 76% slowed progression of retinopathy by 54%; reduced the risk of clinical neuropathy by 60% albuminuria by 54% Arch Ophthalmol. 1995; 113:36-51

Diabetic disease DR Diabetic Retinopathy Diabetic maculopathy

CLINICAL CLASSIFICATION OF DIABETIC RETINOPATHY Background Pre-proliferative Proliferative End-stage diabetic eye disease

Background Diabetic retinopathy Microaneurysms Screening R1

Pre proliferative Retinopathy R2 Dot and Blot haemorrhages Venous beading in two or more quadrants Intraretinal Microvascular Abnormalities No signs of proliferative retinopathy

PPDR R2 Venous beading

High-Risk Proliferative diabetic retinopathy At risk for serious vision loss Any combination of three of the following four findings Presence of vitreous or preretinal hemorrhage. Presence of new vessels (neovascularization, NV) Location of NV on or near the optic disc. Moderate to severe extent of new vessels.

PDR

PDR

Proliferative retinopathy NVD NVE Pre-retinal haemorrhage Laser burn scars

Retinal Diagnostic Tests Fundus Photography Fluorescein Angiography (FA) Optical Coherence Tomography (OCT) Ocular Ultrasonography Electroretinography (ERG)

B-scan Ultrasound

Treatment strategy Strict DM control, Blood Pressure, Cholesterol Annual Screening (DESP) Laser, anti VEGF / steroid injections, Vitrectomy

DIABETIC RETINOPATHY TREATMENT Once DR threatens vision treatments can include: Laser therapy to seal leaking blood vessels (focal laser) Laser therapy to reduce retinal oxygen demand (scatter laser) Anti VEGF or steroid injections Surgical removal of blood from the eye (vitrectomy)

Laser Photocoagulation Laser Photocoagulation is recommended for eyes with: Clinical significant macular edema CSME High risk Proliferative diabetic retinopathy

TREATMENT LASER: Light Amplification by the Stimulated Emission of Radiation Focal Grid Panretinal photocoagulation

Pan-retinal Photocoagulation

Proliferative DR Treatment Vitreous Hemorrhage - 1. Pan-retinal photocoagulation 2. Vitrectomy with laser photocoagulation 3. Intraocular VEGF inhibitor* Traction Retinal Detachment - 1. Observation if not involving the macula 2. Vitrectomy with membrane dissection * Off-label use, controversial

Vitrectomy

Diabetic macular edema Diabetic macular edema is the leading cause of legal blindness in diabetics. Diabetic macular edema can be present at any stage of the disease, but is more common in patients with proliferative diabetic retinopathy.

Meta analysis and review on the effect on bevacizumab id diabetic macular edema Graefes Arch Clin Exp Ophthalmol(2011) 249:15-27

Why is Diabetic macular edema so important? The macula is responsible for central vision. Diabetic macular edema may be asymptomatic at first. As the edema moves in to the fovea (the center of the macula) the patient will notice blurry central vision. The ability to read and recognize faces will be compromised. Macula Fovea

Diabetic maculopathy Hard exudate

Clinically significant macular edema (CSME) Thickening of the retina at or within 500 µm of the center of the macula. Hard exudates at or within 500 µm of the center of the macula, if associated with thickening of the adjacent retina. Area of retinal thickening 1 disc area or larger, within 1 disc diameter of the center of the macula. ETDRS

DIABETIC RETINOPATHY TREATMENT NEWER DEVELOPMENTS: Steroids ; Intravitreal Triamcinolone Anti-VEGF antibody treatment appears to be useful for both macular edema and proliferative retinopathy ; Intravitreal Avastin & Lucentis Long acting steroid implants; Ozurdex and Illuvien http://drcrnet.jaeb.org

DME laser treatment

DME laser treatment * * * * * * * * * * *